175 related articles for article (PubMed ID: 37109292)
41. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
Liao W; Liu Y; Wang X; Jiang X; Tang B; Fang J; Chen C; Hu Z
Acta Radiol; 2009 Mar; 50(2):217-25. PubMed ID: 19096950
[TBL] [Abstract][Full Text] [Related]
42. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
[TBL] [Abstract][Full Text] [Related]
43. Perfusion Maps Acquired From Dynamic Angiography MRI Using Deep Learning Approaches.
Asaduddin M; Roh HG; Kim HJ; Kim EY; Park SH
J Magn Reson Imaging; 2023 Feb; 57(2):456-469. PubMed ID: 35726646
[TBL] [Abstract][Full Text] [Related]
44. Pituitary MRI Standard and Advanced Sequences: Role in the Diagnosis and Characterization of Pituitary Adenomas.
Gadelha MR; Barbosa MA; Lamback EB; Wildemberg LE; Kasuki L; Ventura N
J Clin Endocrinol Metab; 2022 Apr; 107(5):1431-1440. PubMed ID: 34908114
[TBL] [Abstract][Full Text] [Related]
45. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
Provenzale JM; York G; Moya MG; Parks L; Choma M; Kealey S; Cole P; Serajuddin H
AJR Am J Roentgenol; 2006 Oct; 187(4):1036-42. PubMed ID: 16985154
[TBL] [Abstract][Full Text] [Related]
46. Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling.
Huang J; Wang AM; Shetty A; Maitz AH; Yan D; Doyle D; Richey K; Park S; Pieper DR; Chen PY; Grills IS
Magn Reson Imaging; 2011 Sep; 29(7):993-1001. PubMed ID: 21571478
[TBL] [Abstract][Full Text] [Related]
47. Advanced MR imaging techniques in the evaluation of nonenhancing gliomas: perfusion-weighted imaging compared with proton magnetic resonance spectroscopy and tumor grade.
Sahin N; Melhem ER; Wang S; Krejza J; Poptani H; Chawla S; Verma G
Neuroradiol J; 2013 Oct; 26(5):531-41. PubMed ID: 24199813
[TBL] [Abstract][Full Text] [Related]
48. Value of perfusion-weighted MR imaging in the assessment of early cerebral alterations in neurologically asymptomatic HIV-1-positive and HCV-positive patients.
Bladowska J; Knysz B; Zimny A; Małyszczak K; Kołtowska A; Szewczyk P; Gąsiorowski J; Furdal M; Sąsiadek MJ
PLoS One; 2014; 9(7):e102214. PubMed ID: 25013963
[TBL] [Abstract][Full Text] [Related]
49. Comparison of unsupervised classification methods for brain tumor segmentation using multi-parametric MRI.
Sauwen N; Acou M; Van Cauter S; Sima DM; Veraart J; Maes F; Himmelreich U; Achten E; Van Huffel S
Neuroimage Clin; 2016; 12():753-764. PubMed ID: 27812502
[TBL] [Abstract][Full Text] [Related]
50. Combined value of susceptibility-weighted and perfusion-weighted imaging in assessing who grade for brain astrocytomas.
Wang XC; Zhang H; Tan Y; Qin JB; Wu XF; Wang L; Zhang L
J Magn Reson Imaging; 2014 Jun; 39(6):1569-74. PubMed ID: 24987755
[TBL] [Abstract][Full Text] [Related]
51. Meningiomas with conventional MRI findings resembling intraaxial tumors: can perfusion-weighted MRI be helpful in differentiation?
Hakyemez B; Yildirim N; Erdoğan C; Kocaeli H; Korfali E; Parlak M
Neuroradiology; 2006 Oct; 48(10):695-702. PubMed ID: 16896907
[TBL] [Abstract][Full Text] [Related]
52. Brain abscess and cystic brain tumor: discrimination with dynamic susceptibility contrast perfusion-weighted MRI.
Erdogan C; Hakyemez B; Yildirim N; Parlak M
J Comput Assist Tomogr; 2005; 29(5):663-7. PubMed ID: 16163039
[TBL] [Abstract][Full Text] [Related]
53. MR perfusion-weighted imaging may help in differentiating between nonenhancing gliomas and nonneoplastic lesions in the cervicomedullary junction.
Liu X; Kolar B; Tian W; Germin BI; Huang Y; Hu R; Zhong J; Ekholm S
J Magn Reson Imaging; 2011 Jul; 34(1):196-202. PubMed ID: 21618332
[TBL] [Abstract][Full Text] [Related]
54. Clinical applications of dynamic susceptibility contrast perfusion-weighted MR imaging in brain tumours.
Romano A; Rossi Espagnet MC; Calabria LF; Coppola V; Figà Talamanca L; Cipriani V; Minniti G; Pierallini A; Fantozzi LM; Bozzao A
Radiol Med; 2012 Apr; 117(3):445-60. PubMed ID: 21892719
[TBL] [Abstract][Full Text] [Related]
55. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
56. Value of dynamic susceptibility contrast perfusion MRI in the acute phase of transient global amnesia.
Förster A; Al-Zghloul M; Kerl HU; Böhme J; Mürle B; Groden C
PLoS One; 2015; 10(3):e0122537. PubMed ID: 25803440
[TBL] [Abstract][Full Text] [Related]
57. Usefulness of enhancement-perfusion mismatch in differentiation of CNS lymphomas from other enhancing malignant tumors of the brain.
Goyal P; Kumar Y; Gupta N; Malhotra A; Gupta S; Gupta S; Mangla M; Mangla R
Quant Imaging Med Surg; 2017 Oct; 7(5):511-519. PubMed ID: 29184763
[TBL] [Abstract][Full Text] [Related]
58. Differentiation of grade II/III and grade IV glioma by combining "T1 contrast-enhanced brain perfusion imaging" and susceptibility-weighted quantitative imaging.
Saini J; Gupta PK; Sahoo P; Singh A; Patir R; Ahlawat S; Beniwal M; Thennarasu K; Santosh V; Gupta RK
Neuroradiology; 2018 Jan; 60(1):43-50. PubMed ID: 29090331
[TBL] [Abstract][Full Text] [Related]
59. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
60. [Tumors of the sellar region].
Lieb JM; Ahlhelm FJ
Radiologe; 2017 Sep; 57(9):740-747. PubMed ID: 28667391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
